Edgewise Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EWTX research report →
Range $36 – $66
Price Chart
About the company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy.
- CEO
- Kevin Koch
- IPO
- 2021
- Employees
- 127
- HQ
- Boulder, CO, US
Get TickerSpark's AI analysis on EWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.34B
- P/E
- -21.78
- PEG
- 1.25
- P/S
- 0.00
- P/B
- 9.68
- EV/EBITDA
- -21.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.01%
- ROIC
- -48.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,266,000+0.0%
- Op Income
- $-191,406,000
- Net Income
- $-167,795,000-25.4%
- EPS
- $-1.63-12.4%
- OCF Growth
- -31.9%
- FCF Growth
- -30.3%
- 52W High
- $48.51
- 52W Low
- $14.25
- 50D MA
- $42.88
- 200D MA
- $34.80
- Beta
- 0.28
- RSI (14)
- 43
- Avg Volume
- 1.35M
No earnings-call transcripts are available for EWTX yet.
- Free Float
- 74.0%
- Shares Outstanding
- 107.59M
- Float Shares
- 79.59M
of shares held by institutions
225 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 15.52M | 0 |
| Paradigm Biocapital Advisors LP | 10.22M | ▲ 2.85M |
| Ra Capital Management, L.P. | 8.39M | ▼ 2.04M |
| Blackrock, Inc. | 6.61M | ▲ 133.34K |
| Jupiter Topco LLC | 6.08M | ▲ 6.08M |
| Janus Henderson Group Ltd. | 5.92M | ▲ 1.35M |
| Fmr LLC | 5.49M | ▲ 4.47M |
| Novo Holdings A/S | 5.35M | 0 |
| Vanguard Group Inc | 4.87M | ▲ 67.68K |
| Driehaus Capital Management LLC | 4.73M | ▲ 250.68K |
| Perceptive Advisors LLC | 4.37M | ▼ 50.00K |
| Vanguard Capital Management LLC | 3.86M | ▲ 72.51K |
Held by 250 ETFs
Biggest fund positions in EWTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Fox Jonathan C | other | 308 |
| Aug 12, 26 | Nofi Michael | other | 48,750 |
| Aug 12, 26 | Donovan Joanne M. | other | 65,000 |
| Aug 12, 26 | Russell Alan J | other | 65,000 |
| Aug 12, 26 | MOORE JOHN R | other | 65,000 |
| Aug 12, 26 | Derakhshan Behrad | other | 100,000 |
| Aug 12, 26 | Nofi Michael | other | 48,750 |
| Aug 12, 26 | Nofi Michael | other | 24,375 |
| Aug 12, 26 | Donovan Joanne M. | other | 65,000 |
| Aug 12, 26 | Donovan Joanne M. | other | 32,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EWTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on EWTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com · Oct 1
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
seekingalpha.com · Sep 22
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
prnewswire.com · Sep 22
Biotech Options Buzz: UTHR, NMRA, EWTX
schaeffersresearch.com · Sep 18
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
defenseworld.net · Sep 11
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com · Sep 2
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
prnewswire.com · Aug 24
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
seekingalpha.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.